ProQR Therapeutics (PRQR) Short term Debt (2021 - 2025)

ProQR Therapeutics' Short term Debt history spans 3 years, with the latest figure at $4.9 million for Q4 2024.

  • For Q4 2024, Short term Debt changed N/A year-over-year to $4.9 million; the TTM value through Dec 2024 reached $4.9 million, changed N/A, while the annual FY2024 figure was $5.0 million, N/A changed from the prior year.
  • Short term Debt for Q4 2024 was $4.9 million at ProQR Therapeutics, up from $2.6 million in the prior quarter.
  • Across five years, Short term Debt topped out at $5.5 million in Q4 2021 and bottomed at $2.6 million in Q4 2022.
  • The 3-year median for Short term Debt is $4.9 million (2024), against an average of $4.3 million.
  • The largest YoY upside for Short term Debt was 53.27% in 2022 against a maximum downside of 53.27% in 2022.
  • A 3-year view of Short term Debt shows it stood at $5.5 million in 2021, then plummeted by 53.27% to $2.6 million in 2022, then skyrocketed by 91.97% to $4.9 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Short term Debt are $4.9 million (Q4 2024), $2.6 million (Q4 2022), and $5.5 million (Q4 2021).